Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Weight-loss jabs will be made available to the poorest who have the highest need, the Government has said in the NHS 10-year ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...